Initial Real-World Experiences of Pulmonary Vein Isolation and Ablation of Non-Pulmonary Vein Sites Using a Novel Circular Array Pulsed Field Ablation Catheter

dc.contributor.authorYogarajah, Joerg
dc.contributor.authorHutter, Julie
dc.contributor.authorKahle, Patrick
dc.contributor.authorBeaujean, Philipp
dc.contributor.authorTomic, Marko
dc.contributor.authorHain, Andreas
dc.contributor.authorSossalla, Samuel
dc.contributor.authorKuniss, Malte
dc.contributor.authorNeumann, Thomas
dc.date.accessioned2024-12-12T09:05:21Z
dc.date.available2024-12-12T09:05:21Z
dc.date.issued2024
dc.description.abstractBackground and Aims: Various pulsed field ablation (PFA) systems are currently being developed. Recently, a novel CE-approved circular array PFA catheter (PulseSelect™ PFA System, Medtronic, Minneapolis, MN, USA) was introduced. Data on this commercially available system are sparse. The aim was to elucidate real-world data assessing the feasibility, safety, and acute efficacy of pulmonary vein isolation (PVI) and ablation beyond PVI with this novel ablation system. Methods: Consecutive patients with paroxysmal and persistent atrial fibrillation (AF) undergoing first-time ablation with the circular PFA catheter were enrolled in this study. In patients with persistent AF and left atrial (LA) enlargement (LA area > 20 cm2), additional left atrial roof ablation (LARA) was performed. Those with concomitant typical atrial flutter received adjunctive cavo-tricuspid isthmus (CTI) ablation. Results: A total of 100 AF patients were included (29% female, 50% persistent AF). Of these, 33 patients (33%) underwent adjunctive LARA, 1 patient (1%) received posterior wall isolation, and 6 patients (6%) required additional CTI ablation. The skin-to-skin procedural time averaged 66.3 ± 13.8 min, while the fluoroscopy time and dose area product were 13.7 ± 4.7 min and 6.8 ± 4.9 Gycm2, respectively. Acute PVI was achieved in 100% of pulmonary veins. A bidirectional conduction block of the LARA and CTI lines was confirmed in all patients, and no major adverse events were reported. Conclusions: These real-world data demonstrate the feasibility, safety, and acute efficacy of PVI and ablation beyond PVI using a novel circular array PFA catheter in patients with atrial fibrillation and flutter. The system can easily be integrated with standard PVI workflows. Further and larger studies are warranted to assess the clinical long-term effectiveness and safety of this PFA system.en
dc.identifier.urihttps://jlupub.ub.uni-giessen.de/handle/jlupub/20044
dc.identifier.urihttps://doi.org/10.22029/jlupub-19399
dc.language.isoen
dc.rightsNamensnennung 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.ddcddc:610
dc.titleInitial Real-World Experiences of Pulmonary Vein Isolation and Ablation of Non-Pulmonary Vein Sites Using a Novel Circular Array Pulsed Field Ablation Catheter
dc.typearticle
local.affiliationFB 11 - Medizin
local.source.articlenumber6961
local.source.epage12
local.source.journaltitleJournal of Clinical Medicine
local.source.number22
local.source.spage1
local.source.urihttps://doi.org/10.3390/jcm13226961
local.source.volume13

Dateien

Originalbündel
Gerade angezeigt 1 - 1 von 1
Lade...
Vorschaubild
Name:
10.3390_jcm13226961.pdf
Größe:
2.25 MB
Format:
Adobe Portable Document Format